New antibody drug trial offers hope for Hard-to-Treat wet AMD

NCT ID NCT07547228

Recruiting now Disease control Sponsor: Intra-IMMUSG Pte Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new drug called PRL3-zumab in 15 people with wet age-related macular degeneration (nAMD) who have not improved with standard treatments. The drug is given by IV every two weeks for three doses. The study will check for safety and any signs that vision or eye health may improve.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PRL3-zumab (a lab-made antibody given by IV)
What this could lead to: If it works, this could offer a new treatment option for people with wet AMD who have not responded to current therapies.
What could go wrong: This is a very early, small study (15 people) focused on safety. It may not improve vision, and side effects are unknown. Success in this small group does not guarantee broader benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

NUHS Department of Ophthalmology
RECRUITING

Singapore, Singapore

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.